(HealthDay News) — For Medicare beneficiaries after myocardial infarction (MI) hospitalization, statin intolerance is associated with increased risk of recurrent MI and coronary heart disease (CHD) events, according to a study published in the Journal of the American College of Cardiology.

Maria-Corina Serban, MD, PhD, from the University of Alabama at Birmingham, and colleagues studied 105,329 Medicare beneficiaries who began a moderate- or high-intensity statin dosage after MI hospitalization between 2007 and 2013.

The researchers found that, overall, 1.65% of patients had statin intolerance and 52.8% had high statin adherence. Statin intolerance correlated with a 36% higher rate of recurrent MI (41.1 vs 30.1 per 1,000 person-years), a 43% increased rate of CHD events (62.5 vs 43.8 per 1,000 person-years), and a 15% reduced rate of all-cause mortality (79.9 vs 94.2 per 1,000 person-years), compared to beneficiaries with high statin adherence. When comparing beneficiaries with statin intolerance to those with high statin adherence, the multivariate-adjusted hazard ratios were 1.50 (95% confidence interval [CI], 1.30 to 1.73), 1.51 (95% CI, 1.34 to 1.70), and 0.96 (95% CI, 0.87 to 1.06) for recurrent MI, CHD events, and all-cause mortality, respectively.

“Statin intolerance was associated with an increased risk for recurrent MI and CHD events but not all-cause mortality,” the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Amgen, which funded the study.

Related Articles


  1. Serban MC, Colantonio LD, Manthripragada AD, et al. Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction. J Am Coll Cardiol. 21 March 2017. doi: 10.1016/j.jacc.2016.12.036